Organ-on-a-Chip Drug Testing Services
Experience the predictive power of Organ-on-a-Chip technology
Getting started with Organ-on-a-Chip technology has never been easier.
We offer a diverse portfolio of Organ-on-a-Chip drug testing services to support a broad range of standard and custom applications. Researchers can easily partner with our in-house scientific experts and gain access to cutting-edge Organ-on-a-Chip technology for target validation, mechanism of action, and advanced in vitro toxicity studies, at scale.
Standard Service Offerings
Standard service offerings are comprised of validated models and protocols by our team of scientific experts.
Listed below are our standard menu offerings.
Get more clinically predictive in vitro toxicity assessments with Organ-on-a-Chip services before heading into the clinic.
A major challenge of developing orally administered drugs is the limited ability to predict drug-induced gastrointestinal toxicity. The human Duodenum Intestine-Chip combines primary human organoids, endothelial cells, and mechanical forces for improved evaluation of drug candidate safety risk and translation to the clinic.
Drug-induced liver injury (DILI) is one of the most common reasons for the withdrawal of drugs from the market. The quad-culture human Liver-Chip can be used to predict toxicity at clinically relevant drug concentrations and investigate diverse mechanisms of DILI, enabling researchers to de-risk drug candidates before the clinic.
Proximal Tubule Kidney-Chip
Drug-induced nephrotoxicity is a principal reason for drug attrition of therapeutic candidates before, during, and after clinical trials. The co-culture Kidney-Chip leverages primary human cells for more accurate and clinically translatable responses to assess early indicators of nephrotoxicity.
Drug-Drug Interactions Services
Explore potential drug-drug interactions (DDIs) using Organ-on-a-Chip services to better predict human toxicity or treatment failure.
Proximal Tubule Kidney-Chip
During the drug development process, evaluating the effect of xenobiotics on renal transporters is important for establishing pharmacokinetic (PK) profiles, which impact drug response, toxicity, metabolism, and other DDIs. Unlike cell line models, the Kidney-Chip has high expression of renal transporters with in vivo-like function, supporting better DDI assessments to improve the safety profile of novel drug candidates.
Our Organ-on-a-Chip services can support your research into mechanisms of inflammatory response and the efficacy of anti-inflammatory treatments.
Investigate mechanisms of neuroinflammation and drug candidate efficacy in a human-based model of the neurovascular unit with our Brain-Chip services. When exposed to inflammatory stimuli, the Brain-Chip exhibits hallmarks of inflammation, including glial activation and increased blood-brain barrier permeability, enabling insights into pathological mechanisms and drug effect. The Brain-Chip includes microglia, immune cells critical for modeling neuroinflammatory diseases such as Parkinson’s and Alzheimer’s and for evaluating drug efficacy and mechanism of action.
Assess drug candidate efficacy in inflammatory disorders using our Colon Intestine-Chip services. Chronic inflammation in the gastrointestinal tract leads to disorders and diseases resulting in compromised intestinal wall integrity, changes in the microbiome, and dysregulation of immune response. The Colon Intestine-Chip forms a functional and mature colonic intestinal barrier and demonstrates clinically relevant responses when exposed to inflammatory stimuli, enabling mechanistic studies of the inflammatory process and efficacy evaluation of novel drug candidates.
Conduct human-relevant therapeutic efficacy assessment using clinical endpoints for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). By exposing the Liver-Chip to fatty acid stimuli, a mild to moderate fatty liver phenotype can be modeled on-chip, enabling studies into disease mechanisms and therapeutic efficacy assessment.
Custom Collaboration Projects
For when your research needs do not fall neatly into a standard service offering, we offer custom collaboration projects tailored to your application of interest.
A study published in Science Translational Medicine showcases how species-specific versions of the Liver-Chip can be used to identify differences in drug metabolism and toxicity. The study revealed that CYP activities measured in the co-culture human, rat, and dog chips over a 14-day culture period were comparable to, or in some cases greater than, those exhibited by freshly isolated hepatocytes.
In partnership with the Wyss Institute for Biologically Inspired Engineering, a Bone Marrow-Chip was designed to model human response to adverse stimuli as well as genetic abnormalities. Data generated showed this novel chip could be used to study the full cycle of drug-induced bone marrow injury and post-treatment recovery in response to chemotherapeutics and ionizing radiation, which cannot be done using conventional cell-based or animal models. Additionally, the Bone Marrow-Chip was able to successfully model key hematopoietic defects by seeding the chip with cells from a patient with a rare genetic disorder.
In collaboration with Roche, the Emulate team applied the Duodenum Intestine-Chip and Colon Intestine-Chip to assess on-target, off-tumor safety risk of T-cell bispecific antibodies (TCBs) applied directly to the epithelial channel. Conventional preclinical animal models preclude accurate safety assessments due to species differences, and cell lines differ from in vivo tissue in gene expression and response, resulting in limited clinical relevance. Data gathered using both chips demonstrated regional and target affinity-dependent gastrointestinal toxicity in response to TCB treatment, recreating in vivo mechanisms of TCB-mediated toxicity and the identification of a safer TCB candidate; ultimately, opening the potential to determine a safe therapeutic window.
Predicting drug-induced thrombosis using current preclinical cell culture and animal models is difficult due to the complex and specifies-specific response. In a paper published in Clinical Pharmacology and Therapeutics, a team of researchers developed a Blood Vessel-Chip to assess the safety of Hu5c8, a drug candidate that showed unexpected thrombosis in clinical trials. The study was able to recreate the pro-thrombotic effects of Hu5c8 at clinically relevant drug concentrations for the first time in vitro and showed the role of patient-specific biomarkers in assessing thrombotic response, demonstrating the potential to use Organ-on-a-Chip technology for biomarker identification and clinical trial patient stratification.
Species-specific Liver-Chip models have potential future applications for safety testing, disease modeling, and biomarker identification. This experimental approach could also be used to study whether toxicities observed in animal models are translatable to humans.
to Meet Your Needs
All validated Organ-Chip models can be customized for different applications depending on your specific research requirements. We will work with you to expertly design and execute a study to generate quality data to answer your research questions.
Data Analysis & Reporting
Data generated from our services can also be customized to meet your needs. Let us know what you are looking for, and we will explore your options with you.